The Current State of the Treatment of Kidney Cancer
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
- The treatment of kidney cancer can be divided into two categories: anti-angiogenic therapies and mTOR inhibitors.
- Before 2007, the main treatment options were interferon and interleukin-2.
- Many drugs have been approved since 2007, including sorafenib, axitinib, sunitinib, pazopanib, bevacizumab, temsirolimus, and everolimus.
- About 75-80% of patients with kidney cancer have clear cell-type disease.
- Today, no standard of care exists for rare types of kidney cancer.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
